IR August 2026 Resource: IPO Fundamentals for IR & Communications Professionals

​Elizabeth Higgins was most recently the Head of Corporate Communications and Investor Relations at Astria Therapeutics until its acquisition by BioCryst Pharmaceuticals in January 2026. Liz spent the last 7 years leading Astria’s Communications and IR functions through major milestones, including the transition and associated rebrand from Catabasis Pharmaceuticals to Astria Therapeutics, progression of Astria’s lead program into Phase 3, and strategic execution of Astria’s acquisition and its surrounding messaging. Liz cares deeply about amplifying patients’ lived experiences in communications to all stakeholders, including investors, and believes that thoughtful corporate responsibility efforts can both support an organization’s business objectives and meaningfully contribute to broader society. Prior to her time at Astria Therapeutics, Liz worked at Ironwood Pharmaceuticals. She has a BA in International Relations from Bucknell University.